Global clinical trials activity decreases 11.7% in Q1 2020

2 June 2020 (Last Updated June 3rd, 2020 07:20)

Global clinical trials activity decreased by 11.7% in Q1 2020, when compared with the same quarter in 2019, according to GlobalData.

Global clinical trials activity decreases 11.7% in Q1 2020
Credit: Louis Reed on Unsplash.

Global clinical trials activity decreased by 11.7% in Q1 2020, when compared with the same quarter in 2019, according to GlobalData.

Industry-sponsored trials accounted for a 42.3% share of overall activity in Q1 2020, an increase of 1.4% when compared with Q1 2019.

Non-industry-sponsored trials accounted for a 57.7% share of all clinical trials in Q1 2020, marking a decrease of 1.4% when compared with the same period in 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Q1 2020 industry-sponsored clinical trials activity by therapy areas

Oncology was the leading therapy area for industry-sponsored clinical trials in Q1 2020, accounting for a 28.3% share of all trials.

This was followed by infectious disease with a 15.4% share, central nervous system with 13.0%, respiratory with 9.9% and metabolic disorders with 7.8%.

In Q1 2019, oncology led with a 27.1% share, followed by central nervous system with 15.3%, infectious disease with 11.1%, metabolic disorders with 9.3%, and cardiovascular with 7.8%.

Industry-sponsored trials: Q1 2020 vs Q1 2019
Therapy Area Q1 2019 Q1 2020 Activity
Oncology 27.1% 28.3% Increase
Infectious Disease 11.1% 15.4% Increase
Central Nervous System 15.3% 13.0% Decrease
Respiratory 6.5% 9.9% Increase
Metabolic Disorders 9.3% 7.8% Decrease
Cardiovascular 7.8% 7.1% Decrease
Gastrointestinal 6.8% 6.6% Decrease
Immunology 6.4% 4.9% Decrease
Dermatology 6.0% 4.1% Decrease
Hematological Disorders 3.1% 3.7% Increase
Musculoskeletal Disorders 4.1% 3.5% Decrease
Ophthalmology 2.7% 3.2% Increase
Genito Urinary System And Sex Hormones 3.0% 2.3% Decrease
Women’s Health 2.2% 2.1% Decrease
Genetic Disorders 1.7% 1.5% Decrease
Ear Nose Throat Disorders 2.2% 1.4% Decrease
Mouth and Dental Disorders 0.4% 0.7% Increase
Hormonal Disorders 0.8% 0.5% Decrease
Male Health 0.9% 0.4% Decrease
Nutritional Disorders 0.6% 0.4% Decrease
Non Malignant Disorders 0.3% 0.0% Decrease

Most active therapy areas in non-industry-sponsored clinical trials

In Q1 2020 the leading therapy area for non-industry-sponsored clinical trials was central nervous system, accounting for a 21.9% share of all trials.

This was followed infectious disease with a 19.5% share, oncology with 19.3%, respiratory with 12.8%, and cardiovascular with 8.9%.

In Q1 2019, central nervous system held the lead in non-industry-sponsored clinical trials with a 27.1% share, followed by oncology with 19.3%, cardiovascular with 9.5%, gastrointestinal with 8.5%, and metabolic disorders with 8.3%.

Non-Industry-sponsored trials: Q1 2020 vs Q1 2019
Therapy Area Q1 2019 Q1 2020 Activity
Central Nervous System 27.1% 21.9% Decrease
Infectious Disease 7.7% 19.5% Increase
Oncology 19.3% 19.3% Decrease
Respiratory 4.1% 12.8% Increase
Cardiovascular 9.5% 8.9% Decrease
Gastrointestinal 8.5% 6.5% Decrease
Metabolic Disorders 8.3% 5.5% Decrease
Women’s Health 6.2% 5.1% Decrease
Musculoskeletal Disorders 5.8% 5.0% Decrease
Dermatology 3.1% 3.0% Decrease
Immunology 3.5% 3.0% Decrease
Genito Urinary System And Sex Hormones 3.6% 2.6% Decrease
Hematological Disorders 3.7% 2.6% Decrease
Mouth and Dental Disorders 3.2% 2.3% Decrease
Ophthalmology 1.6% 1.7% Increase
Ear Nose Throat Disorders 1.1% 1.4% Increase
Nutritional Disorders 1.1% 0.9% Decrease
Hormonal Disorders 0.9% 0.6% Decrease
Male Health 0.6% 0.6% Decrease
Genetic Disorders 0.8% 0.4% Decrease
Non Malignant Disorders 0.4% 0.3% Decrease

Asia-Pacific region has the most activity for industry-sponsored clinical trials

Asia-Pacific was the most active region for industry-sponsored clinical trials activity in Q1 2020 with a 48.0% share, compared with 51.3% in Q1 2019.

North America was the second most active region with a 36.0% share in Q1 2020, up from 32.5% in Q1 2019, followed by Europe with a 29.2% share in Q1 2020, down from 30.5% in Q1 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 83.8% share in industry-sponsored clinical trials in Q1 2020, compared with 84.0% in Q1 2019. Multinational trials accounted for 16.2% in Q1 2020, against 16.0% in Q1 2019.

Regional activity for non-industry-sponsored clinical trials

Asia-Pacific saw the most non-industry-sponsored clinical trial activity in Q1 2020 with a 53.0% share, up from 52.6% in Q1 2019.

North America held the second position with a 17.2% share in Q1 2020, compared with 15.7% in Q1 2019. This was followed by Europe with a 15.2% share in Q1 2020, as against 14.6% in Q1 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies accounted for 98.9% share of non-industry-sponsored clinical trials in Q1 2020, compared with 98.2% in Q1 2019. Multinational trials accounted for a 1.1% share in Q1 2020, down from 1.8% in Q1 2019.

Clinical trials by phase in Q1 2020

Phase II trials outnumbered all other studies with a 38.8% share for industry-sponsored trials in Q1 2020, compared with 35.2% in Q1 2019.

The share of Phase I trials stood at 30.2% in Q1 2020, down from 37.2% in Q1 2019. Phase III trials increased to 17.8% in Q1 2020, compared with 14.9% in Q1 2019, followed by Phase IV trials with a 13.3% share in Q1 2020, against 12.8% in Q1 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

For non-industry-sponsored clinical trials, Phase II activity decreased to a 41.9% share in Q1 2020, compared with 52.4% in Q1 2019.

Phase IV trials were the second most active with a 20.6% share in Q1 2020, compared with 19.0% in Q1 2019. Phase I trials held a 19.1% share in Q1 2020, against 11.2% in Q1 2019, followed by Phase III trials with an 18.5% share in Q1 2020, over 17.4% in Q1 2019.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.